Monogram Technologies to Showcase AI-Driven Robotic Surgical System at LD Micro Main Event XVII Conference

Monogram Technologies to Present AI-Driven Surgical Robot at Investor Conference

Monogram Technologies Inc. (NASDAQ:MGRM), an AI-driven robotics company specializing in orthopedic surgery, has announced its participation in the upcoming LD Micro Main Event XVII Conference. The event, scheduled for October 29-30, 2024, at the Luxe Sunset Blvd Hotel in Los Angeles, will provide a platform for Monogram to showcase its innovative mBôs precision robotic surgical system 1

1

2

AI-Powered Surgical Precision

At the heart of Monogram's presentation is the mBôs precision robotic surgical system, designed to revolutionize total knee replacement procedures. This AI-driven system autonomously executes optimized paths for high-precision insertion of FDA-cleared mPress press-fit implants. The company aims to achieve better patient outcomes through this advanced technology 1

1

2

Key Features of Monogram's Technology

1. AI and Machine Vision: The mBôs system combines artificial intelligence with advanced machine vision technology (mVision) 1

   1

   2

   2

   .
2. 3D Printing Integration: Monogram's approach incorporates 3D printing to enable patient-optimized orthopedic implants at scale 1

   1

   2

   2

   .
3. Bone-Sparing Implants: The technology aims to provide well-balanced, better-fitting knee replacements while preserving more of the patient's natural bone 1

   1

   2

   2

   .

Conference Presentation Details

Monogram's Chief Financial Officer, Noel Knape, will lead the company's presence at the conference:

• Date: Wednesday, October 30, 2024
• Time: 12:30 PM PT / 3:30 PM ET
• Location: Track 2, Luxe Sunset Blvd Hotel, Los Angeles
• Format: In-person presentation and one-on-one meetings 1

  1

  2

  2

Investors and interested parties can access the live webcast and replay of the presentation through the provided registration link 1

1

2

Related Stories

Monogram Technologies Receives FDA Response for mBôs TKA System and Closes $13 Million Public Offering

Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024, Highlighting AI-Driven Robotic Surgery Advancements

Monogram Technologies' Management Invests $1 Million in Company Stock, Signaling Confidence in AI-Driven Orthopedic Surgery Solutions

LogicMark Inc. to Present at Virtual Emerging Growth Conference

Future Prospects and Regulatory Status

While Monogram has obtained FDA clearance for its mPress implants, the company is still awaiting 510(k) clearance for its robotic products. This regulatory hurdle is crucial for Monogram to market its complete system 1

1

2

The company envisions broader applications for its mBôs precision robot and mVision navigation technology beyond knee replacements, potentially expanding into other areas of orthopedic and general surgery 1

1

2

Investor Relations and Forward-Looking Statements

Monogram Technologies, trading under the NASDAQ symbol MGRM, encourages interested parties to visit their investor relations website for more information. The company has issued cautionary statements regarding forward-looking statements, emphasizing that actual results may vary from projections due to various risks and uncertainties 1

1

2

As Monogram Technologies prepares to showcase its AI-driven surgical innovations at the LD Micro Main Event XVII, the medical technology sector watches closely to see how this blend of artificial intelligence, robotics, and orthopedic expertise might shape the future of surgical procedures.